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practical tricks to identify it reliably according to one 
recent French experienceKeywords:
MALDI-TOF
Haemulonii complex
Candida aurisCandida auris is an emerging pathogenic yeast which can be
potentially multidrug-resistant and responsible for invasive
infections with treatment failure. This species was described in
2009 based on sequencing of ITS (nuclear ribosomal DNA internal
transcribed spacer) and D1/D2 (26S ribosomal DNA large subunit)
regions. Actually, C. auris is phylogenetically related to the
haemulonii complex (Metchnikowiaceae family), which also inclu-
des C. haemulonii stricto sensu, C. ruelliae, C. duobushaemulonii,
C. heveicola, and C. pseudohaemulonii [1]. All these Candida species
are phenotypically very similar, so that they are sometimes
designated as cryptic species, i.e. based on traditional biochemical
methods only, it is particularly challenging for mycologists to
correctly distinguish one species from the others of this complex
[2]. Furthermore, isolates of C. auris were also frequently
misidentiﬁed with other distinct yeast species such as
C. lusitaniae and C. famata.
Recently, several C. auris outbreaks have been described 
worldwide in hospital settings, including both cases of casual 
colonization and cases of true infection. For instance, 50 patients 
were detected to host this yeast within a single cardio-thoracic 
surgery center in England (April 2015–July 2016), including 
22 with probable or proven infection [3]; 33 cases of C. auris 
fungemia were notiﬁed in a surgical intensive care unit in Spain 
(April 2016–November 2016) [4], but many other outbreaks were 
also reported in U.S., India, South America [4]. All these clustered 
isolates suggested nosocomial transmission and potential risk of 
emergence. Since the ﬁrst description of C. auris in the external ear 
canal of a Japanese inpatient in 2009 [1], 90 publications have been 
indexed to the PubMed database about this hot topic in January 
2018. The trend is continuously increasing, e.g. no fewer than 
46 articles were published for the year 2017 alone [4], but 
hopefully no cases had been reported in French laboratories so 
far. We describe herein how we practically proceeded to 
deﬁnitively identify  the  ﬁrst  C.  auris  train  isolated in  FrancePlease cite this article in press as: Desoubeaux G, et al. Candida auris in
reliably according to one recent French experience. Journal D
med.2018.02.011from a 58 year-old-Lebanese man who was hospitalized for liver
transplantation because of severe cirrhosis, and how we
implemented adequate means for controlling its widespreading.
Two months before arriving in France, the patient travelled in
India and Iran for medical purposes. He probably acquired there
several highly-resistant microorganisms, e.g. azole-resistant
C. glabrata, ﬂuconazole – and echinocandin-resistant Geotrichum
fragrans, carbapenem-resistant Escherichia coli, vancomycin-resis-
tant Enterococcus faecium – all isolated from digestive samples –,
and a E. coli strain with extended spectrum b-lactamase – in ascites
ﬂuid. In addition, a C. auris strain was iteratively isolated 11 times
in our patient over a 52-day-long period of hospitalization (eight
times in throat, one time in rectum, in urines and in peritoneal
ﬂuid). On CAN21 chromogenic culture medium (BioMe´rieux,
Marcy-L’E´toile, France), colonies grew quite slowly at 30–378C.
They appeared initially whitish, and then displayed a light reddish-
pink color, very close to this of C. kefyr or C. tropicalis (Fig. 1A).
However, the strain was still able to readily grow at 37–428C, and
in contrast to the two aforementioned species and to C. haemulonii,
its microscopic observation did not show ﬁlamentous or pseudo-
ﬁlamentous hyphae (Fig. 2B). Thus, we went ahead with
identiﬁcation testing through MALDI-TOF (matrix associated laser
desorption ionization–time of ﬂight) mass spectrometry (MS)
[5]. Using the Microﬂex LT1 instrument (Bruker Daltonics, Bremen,
Germany) and the software FlexControl1 v3.4 with default
settings, our MALDI Biotyper Compass IVD1 database v4.2.50
was able to suggest C. auris as possible species name for 64.71%
attempts (i.e. each isolate was tested in duplicate, but around one
third were left unidentiﬁed) (Fig. 2). When present in the top-ten
identiﬁcation listing, C. auris was proposed 81.81% ranked in ﬁrst
position and 72.72% repeated at least a second time in this listing
(mostly in second and third position). However, the log-score
values were constantly low, i.e. the mean value was only
1.59  0.18/3, and the most elevated score was 1.89 which theoreti-
cally allows only mild reliability, according to the manufacturer’s
recommendations. Instead, a lot of bacteria names were suggested
among the identiﬁcation listing, like those belonging to the
Actinomycetales order (27.03% of the top-ten ranking, including
Arthrobacter, Agromyces, Corynebacterium, . . . species) or the Lacto-
bacillales (13.51%, e.g. species of the Lactobacillus and Streptococcus
genera), Burkholderiales (13.51%, mostly Burkholderia species), and
Pseudomonales (11.71%, mostly Pseudomonas species) orders. In only
7.20% cases, alternative fungal names were proposed, including 2.70%
Cryptococcus species which are nonetheless phylogenetically kind
very different from Candida species. A posteriori, we thought that
these poor results were maybe due to the limited number of validated
main mass spectra (MSP) that are referenced in the MALDI Biotyper
Compass IVD1 database for C. auris: only three that come from
Japanese (DSM 21092T CBS) and Korean (KCTC_17809 CBS and
KCTC_17810 CBS) isolates. Besides according to our experience, the
manual full-tube extraction for MS did not better than the direct contemporary mycology labs: A few practical tricks to identify it
e Mycologie Me´dicale (2018), https://doi.org/10.1016/j.myc-
Fig. 1. Phenotypic features of Candida auris in in vitro cultures. A. Macroscopic observation after 72 h-incubation at 378C on CAN21 chromogenic culture medium (BioMe´rieux,
Marcy-L’E´toile, France). C. auris colonies are small and usually develop a reddish-pink color after  48 h culture (red arrows). On non-chromogenic Sabouraud conventional
culture plate, colonies usually stay creamy white, whereas they rather display a light purple color on BBL CHROMagar Candida1medium (Becton Dickinson, Le-Pont-de-Claix,
France). B. Microscopic observation after 72h-incubation at 378C (fresh mounting, magniﬁcation  1000). C. auris is small yeast that does not produce ﬁlamentous or pseudo-
ﬁlamentous hyphae, but it can form budding.
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MYCMED-777; No. of Pages 4on-plate extraction. This ﬁnding was contradictory with previous
reports [6]. Anyway, strain identiﬁcation was ﬁnally unambiguously
conﬁrmed by DNA sequencing of the D1/D2 (query cover = 100%;
identity = 99% of similarity with sequence of UZ1447_15 type strain
for 326 bp sequence) and ITS (query cover = 100%; 99% of similarity
with sequence of CBS 10913 type strain for 400 bp sequence) regions.
GenBank accession No. MG736297 was granted to the D1/D2 strain
sequence. Concomitantly, correct identiﬁcation was not achievable
through auxanogram galleries: API20C1 system (BioMe´rieux, Marcy-
L’E´toile, France) provided Rhodotorula glutinis (percentage of identiﬁ-
cation (%id) = 98.3%; T-index = 0.54) as alternative name (but urease
test in tube was of course negative), and ID32C1 biochemical
platform (BioMe´rieux, Marcy-L’Etoile, France) gave Candida sake
(%id = 98.1%; T-index = 0.64), but noteworthy both biochemical
galleries don’t have C. auris in their respective libraries. Thus, we
suggest that identiﬁcation of R. glutinis by auxanogram system should
trigger additional investigation if fungal colonies are not naturally
pink-colored on conventional non-chromogenic culture plates.
Besides, Vitek MS1 system (BioMe´rieux, Marcy-L’E´toile, France) didn’t
succeed in identifying C. auris when the test was performed with the
current IVD (in vitro diagnosis) v3.2 database, probably because the
latter includes no reference MSP for this species yet (same comment
with the current Andromas1 [Paris, France] MS database). Likewise,
Vitek-21 automated instrument (BioMe´rieux, Marcy-L’E´toile, France)
was shown to commonly misdiagnose C. auris as other yeast [2,5];
besides, an Indian study found that 88.2% of the 102 clinical isolates,
previously identiﬁed as C. haemulonii or C. famata with this system,
were actually C. auris [5].
Susceptibility of our C. auris strain to antifungal drugs was in
vitro assessed according to the E-test1 (BioMe´rieux, Marcy-L’E´toile,
France) and EUCAST (European committee for antimicrobial
susceptibility testing) methods [7]; elevated minimal inhibition
concentrations (MICs) were consistently observed for ﬂucytosine
and ﬂuconazole (> 32 mg/L) with both techniques. Anyway,
determination of MICs seems critical in light of the high probability
of resistance acquisition in C. auris, e.g. 90% clinical strains display
high MIC to ﬂuconazole and 35% to amphotericin B (herein, MIC for
amphotericin B was estimated at 0.5 mg/L) [8]. Very recently, somePlease cite this article in press as: Desoubeaux G, et al. Candida auris in
reliably according to one recent French experience. Journal D
med.2018.02.011authors proposed speciﬁc guidelines deﬁning the MIC breakpoints
and the epidemiological cut-off for C. auris species [9].
Following the ﬁrst detection of C. auris in our department, we
decided to apply very intense means of decontamination [3,8], so
that to avoid selection of this strain and its widespreading in our
mycology laboratory [10,11]. The Center for Diseases Control and
prevention (Atlanta CDC) speciﬁcally recommends use of a
Environmental Protection Agency (EPA)-registered hospital-grade
disinfectant (List K) effective against Clostridium difﬁcile spores
(https://www.cdc.gov/fungal/diseases/candidiasis/
c-auris-infection-control.html) [12]. Indeed, experimental works
recently showed signiﬁcant higher length of C. auris survival on
health care surfaces: at day 28, 3.0 Log10 colony forming units
(CFU) viable cells vs. 2.6 CFU for C. parapsilosis (P < 0.05)
[10]. Likewise, quaternary ammonium products, e.g. Surfanios
Premium1 (Laboratoire Anios, Lille – Hellemmes, France), exhibited
poor activity against C. auris (in average, reduction of only 1.0Log10
CFU vs. 6.0 for Staphylococcus aureus), whereas chlorine, peracetic
acid and hydrogen peroxide remained quite effective (respective
mean reduction of 6.0, 5.0, and 5.5 Log10 CFU, like for C. albicans,
C. glabrata and S. aureus; P > 0.05) [11]. Herein, every C. auris
isolate was conﬁned in a sealed plastic bag and moved to the fridge
at + 48C. Horizontal surfaces, plus all items and furniture that may
have come into contact with the strain, were daily cleaned by
thorough wet wiping and by application of bleach, 2.6% chlorine in
cold water (Avix Javel1 pH12, Coldis, Entraigues-sur-la-Sorgue,
France). Floor was similarly treated thrice weekly. Besides, UV
treatment was implemented for the microbiological ﬂow hoods
during 30 min, instead of 5 min, because data are limited about
hands-free disinfection methods. All these efforts were sustained
for four weeks following the last isolate [10].
The patient ﬁnally died 52 days after hospital admission.
Meanwhile, contact individuals were screened thrice by sampling
urines, rectum, axillae and throat. Detection was also carried out in
exposed patients weekly by cutaneous swabbing of the groins and
the axillae. Altogether, no proofs occurred neither for C. auris
fungemia nor transmission of the strain to other patients of our
facility. contemporary mycology labs: A few practical tricks to identify it
e Mycologie Me´dicale (2018), https://doi.org/10.1016/j.myc-
Fig. 2. Example of mass spectra for one Candida auris isolate based on analysis with the Microﬂex LT1 instrument (Bruker Daltonics, Bremen, Germany) and with the MALDI
Biotyper Compass Explorer v4.1.80.7 (Build [80])1 software (Bruker Daltonics, Bremen, Germany). A. Normalized spectrum (in-gel view). B. Normalized spectrum (classic
view). Sixteen MSP peaks were theoretically expected to be present (frequency = 100%). C. Comparison of spectra with various strains of the database (from top to bottom):
C. auris DSM 21092 T CBS (log-score value = 1.81), C. haemulonii 70624 T DSM (log-score value = 0.98), C. pseudohaemulonii KCTC 17807 CBS (log-score value = 0.82), and
C. duobushaemulonii MY 916_09 ERL (log-score value = 0.87), according to the MALDI Biotyper1 MSP identiﬁcation standard method v1.1 (frequency threshold for spectra
adjusting = 50%, frequency threshold for score calculation = 5%, max mass error of the raw spectrum = 2000 Da, desorption mass tolerance of the adjusted spectrum = 250 Da,
furthermore accepted mass tolerance for a peak = 600 Da). Our isolate is represented in the upper part of each panel, the reference spectra of the database appear in blue in the
lower part of each (thresholds of composite correlation index: < 0.80, red–low matching; 0.80–0.90, yellow–moderate matching; > 0.90, green–high matching). arb:
Arbitrary; intens.: Intensity; m: Mass; rel. int.: Relative intensity; z: ionic charge.
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come back from tropical countries, especially from Asia but also
from Middle East, because they are likely to vehicle unusual and
emerging highly-resistant microorganisms, including fungal spe-
cies like C. auris. Although this yeast species remains rare in
Western countries, its real prevalence in healthcare settings may
have been perhaps underestimated so far, because of unreliable
methods of identiﬁcation [2]. However, it seems critical for clinical
mycology laboratories to accurately and rapidly identify this
microorganism to aid in preventing healthcare-associated out-
breaks. For such a purpose, updating the reference databases with
well-identiﬁed isolates is imperative.
Funding
This work was supported by none.
Disclosure of interest
The authors declare that they have no competing interest. They
have submitted the ICMJE form.Please cite this article in press as: Desoubeaux G, et al. Candida auris in
reliably according to one recent French experience. Journal D
med.2018.02.011Acknowledgment
We thank the patient for his cooperation and the CNRMA,
Institut Pasteur, Paris, France, for its precious help in investigating
the case and in conﬁrming the correct identiﬁcation (special
thanks to Dr. Marie Desnos-Ollivier for her thorough reviewing of
the manuscript). The authors are also very grateful to Jeannine
Brisacier for all the decontamination means she had to apply in the
lab.
References
[1] Satoh K, Makimura K, Hasumi Y, Nishiyama Y, Uchida K, Yamaguchi H. Candida
auris sp. nov., a novel ascomycetous yeast isolated from the external ear canal
of an inpatient in a Japanese hospital. Microbiol Immunol 2009;53:41–4.
http://dx.doi.org/10.1111/j.1348-0421.2008.00083.x.
[2] Kathuria S, Singh PK, Sharma C, Prakash A, Masih A, Kumar A, et al. Multidrug-
resistant Candida auris misidentiﬁed as Candida haemulonii: characterization
by Matrix-assisted laser desorption ionization-time of ﬂight mass spectrome-
try and DNA sequencing and its antifungal susceptibility proﬁle variability by
Vitek 2. CLSI broth microdilution, and Etest method. J Clin Microbiol
2015;53:1823–30. http://dx.doi.org/10.1128/JCM. 00367-15.
[3] Schelenz S, Hagen F, Rhodes JL, Abdolrasouli A, Chowdhary A, Hall A, et al. First
hospital outbreak of the globally emerging Candida auris in a European contemporary mycology labs: A few practical tricks to identify it
e Mycologie Me´dicale (2018), https://doi.org/10.1016/j.myc-
Letter to the editor/Lettre au re´dacteur / Journal de Mycologie Me´dicale xxx (2018) xxx–xxx4
G Model
MYCMED-777; No. of Pages 4hospital. Antimicrob Resist Infect Control 2016;5:35. http://dx.doi.org/
10.1186/s13756-016-0132-5.
[4] Chowdhary A, Sharma C, Meis JF. Candida auris: a rapidly emerging cause of
hospital-acquired multidrug-resistant fungal infections globally. PLoS Pathog
2017;13:e1006290. http://dx.doi.org/10.1371/journal.ppat.1006290.
[5] Grenfell RC, da Silva Junior AR, Del Negro GMB, Munhoz RB, Gimenes VMF,
Assis DM, et al. Identiﬁcation of Candida haemulonii complex species: Use of
ClinProTools(TM) to overcome limitations of the Bruker Biotyper(TM). Vitek
MS(TM) IVD, and Vitek MS(TM) RUO databases. Front Microbiol 2016;7:940.
http://dx.doi.org/10.3389/fmicb.2016.00940.
[6] Mizusawa M, Miller H, Green R, Lee R, Durante M, Perkins R, et al. Can
multidrug-resistant Candida auris be reliably identiﬁed in clinical microbiolo-
gy laboratories? J Clin Microbiol 2017;55:638–40. http://dx.doi.org/10.1128/
JCM. 02202-16.
[7] Pfaller MA, Andes D, Diekema DJ, Espinel-Ingroff A, Sheehan D. CLSI Subcom-
mittee for Antifungal Susceptibility Testing. Wild-type MIC distributions,
epidemiological cutoff values and species-speciﬁc clinical breakpoints for
ﬂuconazole and Candida: time for harmonization of CLSI and EUCAST broth
microdilution methods. Drug Resist Updat Rev Comment Antimicrob Anticancer
Chemother 2010;13:180–95. http://dx.doi.org/10.1016/j.drup.2010.09.002.
[8] Government of United Kingdom. Candida auris: laboratory investigation,
management and infection prevention and control n.d. https://www.gov.
uk/government/publications/candida-auris-laboratory-investigation-
management-and-infection-prevention-and-control [accessed December 28,
2017].
[9] Arendrup MC, Prakash A, Meletiadis J, Sharma C, Chowdhary A. Comparison of
EUCAST and CLSI reference microdilution MICs of eight antifungal compounds
for Candida auris and associated tentative epidemiological cut-off values. Anti-
microb Agents Chemother 2017;61. http://dx.doi.org/10.1128/AAC.00485-17.
[10] Welsh RM, Bentz ML, Shams A, Houston H, Lyons A, Rose LJ, et al. Survival,
persistence, and isolation of the emerging multidrug-resistant pathogenic
yeast Candida auris on a plastic health care surface. J Clin Microbiol
2017;55:2996–3005. http://dx.doi.org/10.1128/JCM.00921-17.
[11] Cadnum JL, Shaikh AA, Piedrahita CT, Sankar T, Jencson AL, Larkin EL, et al.
Effectiveness of disinfectants against Candida auris and other Candida species.
Infect Control Hosp Epidemiol 2017;38:1240–3. http://dx.doi.org/10.1128/
JCM.00921-17.Please cite this article in press as: Desoubeaux G, et al. Candida auris in
reliably according to one recent French experience. Journal D
med.2018.02.011[12] US EPA O. LIST K: EPA’s registered antimicrobial products effective against
Clostridium difﬁcile spores. US EPA; 2015 [https://www.epa.gov/
pesticide-registration/
list-k-epas-registered-antimicrobial-products-effective-against-clostridium
(accessed February 21 2018)].
G. Desoubeauxa,*, E´. Baillya, C. Guillaumea, M.-A. De Kyvona, A.-
C. Tellierb, V. Morangec, L. Bernardd, E. Salame´e, R. Quentinc,f,
J. Chandeniera
aService de parasitologie, mycologie, me´decine tropicale, poˆle de biologie
me´dicale, hoˆpital Bretonneau, CHU de Tours, 1er e´tage du Baˆtiment B2A,
2, boulevard Tonnelle´, 37044 Tours, France
bRe´animation chirurgicale, CHU de Tours, 37044 Tours, France
cEquipe ope´rationnelle d’hygie`ne, CHU de Tours, 37044 Tours, France
dMe´decine interne & maladie infectieuse, CHU de Tours, 37044 Tours,
France
eTransplantation he´patique, CHU de Tours, 37044 Tours, France
fComite´ de lutte contre les infections nosocomiales, CHU de Tours,
37044 Tours, France
*Corresponding author
E-mail address: guillaume.desoubeaux@univ-tours.fr
(G. Desoubeaux).
Received 31 January 2018
Received in revised form 21 February 2018
Accepted 24 February 2018
Available online xxx contemporary mycology labs: A few practical tricks to identify it
e Mycologie Me´dicale (2018), https://doi.org/10.1016/j.myc-
